Dolo, Housseini Coulibaly, Yaya I Sow, Moussa Dembélé, Massitan Doumbia, Salif S Coulibaly, Siaka Y Sangare, Moussa B Dicko, Ilo Diallo, Abdallah A Soumaoro, Lamine
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for Bakoye and Falémé, Mali, supported policy-shifting from morbidity control to elimination of transmission (EOT). These foci are coendemic with lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis)...
Santoso, Yahya, Supranelfy, Yanelza Suryaningtyas, Nungki Hapsari Taviv, Yulian Yenni, Aprioza Arisanti, Maya Mayasari, Rika Mahdalena, Vivin Nurmaliani, Rizki
...
Published in
The Korean Journal of Parasitology
Belitung district in Bangka-Belitung Province, Indonesia with a population of 0.27 million is endemic for Brugia malayi and 5 rounds of mass drug administration (MDA) were completed by 2010. Based on the results of 3 transmission assessment surveys (TAS), the district is declared as achieving elimination of lymphatic filariasis (LF) in 2017. The fi...
Lammie, Patrick J Gass, Katherine M King, Jonathan Deming, Michael S Addiss, David G Biswas, Gautam Ottesen, Eric A Henderson, Ralph
Published in
International Health
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established with the ambitious goal of eliminating LF as a public health problem. The remarkable success of the GPELF over the past 2 decades in carrying out its principal strategy of scaling up and scaling down mass drug administration has relied first on the development of a rigor...
Turner, Hugo C
Published in
International Health
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established by the WHO in 2000. It aims to eliminate lymphatic filariasis as a public health problem. This paper summarises the key estimates of the cost-effectiveness and economic benefits related to the mass drug administration (MDA) provided by the GPELF. Several studies have inv...
Williams, Tijana Taylor, Rachel Iwamoto, Minne Hida, Takayuki Gusovsky, Fabian
Published in
International Health
World Health Assembly Resolution 50.29, adopted in 1997, committed the World Health Organization (WHO) and its member states to eliminate lymphatic filariasis (LF) as a public health problem. In 2000, to support this ambitious goal and the health ministries in the >70 LF-endemic countries, the Global Programme to Eliminate Lymphatic Filariasis (GPE...
Ottesen, Eric A Horton, John
Published in
International Health
The development of the World Health Organization's Global Programme to Eliminate Lymphatic Filariasis (GPELF) can be interpreted through many different lenses—e.g. one focusing on the health or economic plight of affected individuals and populations, another tracking the individuals and organizations responsible for building the programme or, as in...
Kapa, D Ramaiah Mohamed, Ahmed Jamsheed
Published in
International Health
Background The South-East Asia regional programme to eliminate lymphatic filariasis (LF) was launched in 2000. This study presents the progress and impact of the programme in the region. Methods Mass drug administration (MDA) and morbidity management data were accessed from the WHO preventive chemotherapy databank. The status of the programme in th...
Krentel, Alison Gyapong, Margaret McFarland, Deborah A Ogundahunsi, Olumide Titaley, Christiana R Addiss, David G
Published in
International Health
Since the launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, more than 910 million people have received preventive chemotherapy for lymphatic filariasis (LF) and many thousands have received care for chronic manifestations of the disease. To achieve this, millions of community drug distributors (CDDs), community membe...
Mackenzie, Charles D Mante, Sunny
Published in
International Health
Clinical lymphatic filariasis (LF) is a debilitating, disfiguring medical condition with severe psychosocial consequences for patients and their families. Addressing these patients’ medical needs is a major component of the global programme to eliminate lymphatic filariasis (GPELF). In the 20 y of providing a minimal package of care many thousands ...
Weil, Gary J Jacobson, Julie A King, Jonathan D
Published in
International Health
The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination c...
